We are live on ! Find out more
NLSPW

NLS Pharmaceutics Warrant

Delisted

NLSPW was delisted on the 30th of October, 2025.

5 hedge funds and large institutions have $886K invested in NLS Pharmaceutics Warrant in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+5
Holders Change %
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$475K +$455K +500,000 New
Hudson Bay Capital Management
2
Hudson Bay Capital Management
Connecticut
$190K +$182K +200,000 New
WVP
3
Worth Venture Partners
New Jersey
$185K +$177K +194,560 New
WAM
4
Warberg Asset Management
Illinois
$33K +$31.8K +35,000 New
UBS Group
5
UBS Group
Switzerland
$3K +$2.84K +3,119 New

NLSPW Hedge Fund Activity: Q1 2021 in Review

5 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2021, worth a combined $886K.

Buyers outnumbered sellers: 5 funds opened new NLSPW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $455K.

  • 5 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $886K of NLS Pharmaceutics Warrant stock for Q1 2021.
  • 5 funds opened new NLS Pharmaceutics Warrant positions in Q1 2021 and 0 closed out, a net change of +5 holders.
  • The largest NLS Pharmaceutics Warrant buyer in Q1 2021 was Armistice Capital, an estimated $455K added.

Based on aggregated 13F filings for Q1 2021.